Home/Hansa Biopharma/Evan Ballantyne

EB

Evan Ballantyne

Chief Financial Officer

Hansa Biopharma

Therapeutic Areas

Autoimmune Diseases Transplantation Gene Therapy

Hansa Biopharma Pipeline

Drug	Indication	Phase
Imlifidase	Desensitization in Kidney Transplantation	Approved (EU)
HNSA-5487	Next-Generation IgG-cleaving Enzyme	Preclinical/Clinical

Leadership Team at Hansa Biopharma

Renée Aguiar-Lucander

Chief Executive Officer

Chief Scientific & Technology Officer

Maria Törnsén

Chief Operating Officer and President U.S.

View full Hansa Biopharma profile